Non‐Enzymatic Hybrid Catalysis for Stereoconversion of l ‐Amino Acid Derivatives to d ‐Isomers

Picolinaldehyde-Zinc(II)-Palladium(0) Catalytic System for the Asymmetric α-Allylation of N-Unprotected Amino Esters

Reported in this work is a synergistic ternary achiral picolinaldehyde-Zn(II)-chiral palladium complex system for the highly enantioselective α-allylation of N-unprotected amino esters. By utilizing a variety of allylic carbonates or vinyl benzoxazinanones as substrates, α-allyl α-amino esters were obtained in high yields (up to 96 %) with high enantioselectivities (up to 98 % ee). Control experiments suggest that the coordination of Zn(II) with the Schiff base intermediate enhances the acidity of the α-C-H bonds of amino esters, thereby favoring α-allylation over intrinsic N-allylation. Furthermore, NMR studies reveal an interaction between the chiral palladium complex and the Zn(II)-Schiff base intermediate, leading to the formation of a picolinaldehyde-Zn(II)-Pd(0) catalytic system.

Tailor-Made Amino Acids in Pharmaceutical Industry: Synthetic Approaches to Aza-Tryptophan Derivatives

Over the recent years there has been a noticeable upsurge of interest in aza-analogs of tryptophan which are isosteric to the latter and found numerous applications in medicinal, bioorganic chemistry, and peptide research. In the present review article, five aza-tryptophan derivatives are profiled, including aza-substitution in the positions 2, on the five-membered ring, as well as in positions 4, 5, 6, and 7 on the six-membered ring. A detailed and comprehensive literature overview of the synthetic methods for the preparation of these aza-tryptophans is presented and general facets of the biological properties and most promising applications are discussed.

New pharmaceuticals approved by FDA in 2020: Small-molecule drugs derived from amino acids and related compounds

Amino acids (AAs) play an important role in the modern health industry as key synthetic precursors for pharmaceuticals, biomaterials, biosensors, and drug delivery systems. Currently, over 30% of small-molecule drugs contain residues of tailor-made AAs or derived from them amino-alcohols and di-amines. In this review article, we profile 12 AA-derived new pharmaceuticals approved by the FDA in 2020. These newly introduced drugs include Tazverik (epithelioid sarcoma), Gemtesa (overactive bladder), Zeposia (multiple sclerosis), Byfavo (induction and maintenance of procedural sedation), Cu 64 dotatate, and Gallium 68 PSMA-11 (both PET imaging), Rimegepant (acute migraine), Zepzelca (lung cancer), Remdesivir (COVID-19), Amisulpride (nausea and vomiting), Setmelanotide (obesity), and Lonafarnib (progeria syndrome). For each compound, we describe the spectrum of biological activity, medicinal chemistry discovery, and synthetic preparation.

Preparation of racemic α-amino acid standards for accurate mass spectrometric analysis via racemization catalyzed by a hydrophobic pyridoxal derivative

Racemic α-amino acid standards for chiral metabolomics were prepared from l-α-amino acids using a hydrophobic pyridoxal derivative, namely 3-hydroxy-2-methyl-5-((octyloxy)methyl)isonicotinaldehyde (OPy), as the racemization catalyst. Among the 19 tested proteinogenic amino acids, 13 (including the generally unstable asparagine, glutamine, and tryptophan) underwent efficient racemization/epimerization under mildly basic conditions at room temperature, while solid-phase extraction allowed for effective and simple catalyst removal and amino acid recovery, obviating the need for chromatographic separation and recrystallization. Isotopically labeled racemic amino acids are commonly employed as internal standards for highly accurate mass spectrometric analysis. However, as isotopically labeled d-amino acids are often unavailable or highly expensive, the developed method was used to prepare racemic labeled amino acids, which were shown to enhance the repeatability and accuracy of d,l-amino acid quantitation in human urine by liquid chromatography-mass spectrometry (LC-MS). Given that our method should also be applicable to non-proteinogenic α-amino acids and the N-termini of peptides, the present study is expected to accelerate the development of LC-MS-based chiral metabolomics.

Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019

Amino acids (AAs) are among a handful of paramount classes of compounds innately involved in the origin and evolution of all known life-forms. Along with basic scientific explorations, the major goal of medicinal chemistry research in the area of tailor-made AAs is the development of more selective and potent pharmaceuticals. The growing acceptance of peptides and peptidomimetics as drugs clearly indicates that AA-based molecules become the most successful structural motif in the modern drug design. In fact, among 24 small-molecule drugs approved by FDA in 2019, 13 of them contain a residue of AA or di-amines or amino-alcohols, which are commonly considered to be derived from the parent AAs. In the present review article, we profile 13 new tailor-made AA-derived pharmaceuticals introduced to the market in 2019. Where it is possible, we will discuss the development form drug-candidates, total synthesis, with emphasis on the core-AA, therapeutic area, and the mode of biological activity.

Cyclic tailor-made amino acids in the design of modern pharmaceuticals

Tailor-made AAs are indispensable components of modern medicinal chemistry and are becoming increasingly prominent in new drugs. In fact, about 30% of small-molecule pharmaceuticals contain residues of tailor-made AAs or structurally related diamines and amino-alcohols. Cyclic tailor-made AAs present a particular value to rational structural design by virtue of their local conformational constraints and are widely used in lead optimization programs. The present review article highlights 34 compounds, all of which are derived from cyclic AAs, representing recently-approved, small-molecule pharmaceuticals as well as promising drug candidates currently in various phases of clinical study. For each compound, the discussion includes the discovery, therapeutic profile and optimized synthesis, with a focus on the preparation of cyclic tailor-made AA as the principal structural feature. The present review article is intended to serve as a reference source for organic, medicinal and process chemists along with other professionals working in the fields of drug design and pharmaceutical discovery.